Physician profile
Ralph S Baker
NPI 1861430043
$7,909.02
in general payments reported to CMS, 2019-2025
20 companies · $2,935 in 2025
The $2,935 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,795 · 2020: $61.96 · 2021: $104 · 2022: $483 · 2023: $1,210 · 2024: $1,320 · 2025: $2,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,995 · Travel and Lodging: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,995.03 |
| Travel and Lodging | $1,470.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,822.59 | 2022-2025 | Onefit Contact Lens, Misight Contact Lens, Cvi Contact Lens |
| Alcon Vision LLC | $1,579.32 | 2019-2025 | Hydrus Microstent, Total30, Precision7 |
| Biotissue Holdings INC. | $934.98 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $756.67 | 2022-2025 | Infuse, Alden Scleral Zenlens, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $285.89 | 2019-2021 | |
| Oyster Point Pharma, INC. | $230.20 | 2023-2025 | Tyrvaya |
| Sight Sciences, INC. | $160.01 | 2022 | |
| Glaukos Corporation | $155.13 | 2025 | Idosetr |
| Tarsus Pharmaceuticals, INC. | $152.51 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $124.07 | 2019 | |
| Abbvie INC. | $123.08 | 2023-2024 | Lumigan, Alphagan P, Vuity |
| Mallinckrodt Hospital Products INC. | $115.65 | 2023-2024 | Acthar |
| Rxsight INC | $111.74 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $99.45 | 2021-2023 | |
| Synergeyes, INC. | $70.00 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $58.41 | 2025 | Vevye |
| Menicon America INC | $48.57 | 2019 | |
| Dompe US, INC. | $38.15 | 2024-2025 | Oxervate |
| Topcon Healthcare, INC. | $25.10 | 2024 | |
| Johnson & Johnson Vision Care, INC. | $17.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.